Obesity is increasingly recognized as a multi-causal chronic disease that leads to structural and physiological abnormalities and functional impairments. Despite the growing prevalence and substantial burden of obesity in terms of health-related quality of life (HRQoL), healthcare utilization, and healthcare costs, obesity remains under-diagnosed and under-treated. The recent recognition that obesity is associated with increased risk of morbidity and mortality with coronavirus disease 2019 (COVID-19) shines a light on the fact that obesity is characterized by higher prevalence of physiologic alterations, such as chronic inflammation and impaired respiratory function, when compared to the non-obese state.
This live and OnDemand webcast will include interactive animated 3-D models, and a live Q&A session. The discussion, led by expert faculty, will cover pathophysiological features of obesity that influence weight loss, guidelines for screening, diagnosis, and patient counseling, and how to assess efficacy and safety of available and emerging therapies for long-term treatment of obesity.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Novo Nordisk Inc.
Primary care physicians, endocrinologists, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kushner reports that he receives research support from Epitomee Medical. He is a consultant for Novo Nordisk and WW International, Inc.
Dr. Fujioka reports that he is a consultant for Amgen Inc.; Boehringer Ingelheim; Gelesis; Janssen Global Services, LLC; Novo Nordisk; Phenomix Sciences; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers bureau for Novo Nordisk and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Stanford reports that she receives research support from Amazon. She is a consultant for Calibrate Health, Chroma Health, GoodRx, Inc., and Novo Nordisk.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Warren Beckman (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-125-H01-P.
Call us at 877.CME.PROS (877.263.7767).